Bacterial Respiratory Tract Infection, SARS-CoV-2 Infection, Viral Respiratory Tract Infection
Conditions
Keywords
Nursing Home, COVID-19, Respiratory Microbiome
Brief summary
This is a longitudinal, prospective observational study focusing on health-related outcomes relative to potential changes in the respiratory microbiome seen with weekly SARS-CoV-2 testing in nursing home residents.
Detailed description
This study targets the influence of SARS-CoV-2, and the presence of mixed/co-infections on the respiratory microbiome. Their interrelationship will be characterized in a prospective observational study design. The observed changes will be correlated to medical (FEV1, CXR/CT, mortality, morbidity, symptoms) and clinical laboratory parameters (hematology, coagulation, bacterial/viral detection). The study aims at the detection of significant changes in microbiome in the respiratory tract following incidence of SARS-CoV-2 infection. These alterations in the respiratory microbiome will be determined by shotgun metagenomic sequencing. Ultimately, this can provide a better understanding of how SARS-CoV-2 and the presence of other bacteria and viruses affect the composition of the respiratory microbiome and a description of the microbiological etiology of these respiratory tract infections.
Interventions
None listed
Sponsors
Pathnostics
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* All residents of the nursing home facility, (M/F) 65 years or above, who have recently tested positive through Ohio's PARRT Program are eligible * Resident must submit weekly nasal swab sample per nursing home COVID testing guidelines * Clinical suspicion of a new episode of acute respiratory tract infection. * Laboratory confirmed SARS-CoV-2 infection by either a laboratory test, PCR or any other commercial or public health test
Exclusion criteria
* Nursing home residents that are not taking part regularly in weekly screening for SARS-COV-2 or residents that test negative through Ohio's PARRT program cannot be included as part of study analyses * Residents on hospice, residents currently intubated, residents with scheduled transfer to another nursing home facility will not be included in study analyses
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in hematology | Baseline to any timepoint for 4 to 8 weeks | Examine prospective data to identify changes in patient hematology through analysis of complete blood routines for CBC and WBC. |
| Percent of pre-symptomatic SARS-Cov-2 positives and/or bacterial/viral infection | 4-8 weeks | Examine prospective data to determine the percent of pre-symptomatic SARS-CoV-2 positives and/or bacterial/viral infection. This is the asymptomatic period PRIOR to a symptomatic period all during time of PCR positivity. |
| Percent of all acute medical complications | 4-8 weeks | Examine prospective data to determine the prevalence of all medical usual complications and geriatric acquired complications, such as delirium, falls, pressure sores, new infectious disease (UTI), cardiovascular, incidence of acute heart failure \[elevated BNP presence of new ECG abnormalities (ST elevation and/or T-wave inversion), myocardial injury \[reflected by elevation in cardiac troponin levels above the 99th percentile upper reference limit on admission, cerebrovascular disease \[Stroke, stroke subtype (ischemic, cryptogenic , metabolic disease manifestations DKA, hyperosmolar hyperglycemic state (HHS), and severe insulin resistance, Neurological Manifestations \[Anosmia/dysgeusia, Guillen Barre Syndrome, Meningoencephalitis, Encephalomyelitis, myoclonus (generalized), Rhabdomyolysis, VTE, DIC, PE, acute limb ischemia |
| Pulmonary function | Baseline to any timepoint for 4 to 8 weeks | Examine prospective data to determine the the percent change in forced vital capacity (FVC), forced expiratory volume (FEV1), peak expiratory flow (PEF) in patients |
| Chest CT X-ray | Baseline to any timepoint for 4 to 8 weeks | Examine prospective data to determine the percent of lung CT containing consolidation, percent of patients showing reticular patterns, percent containing pure ground-glass opacification, percent containing honeycomb appearance, percent containing Bronchiectasis |
| Percent of SARS-CoV-2 infection | 4-8 weeks | Examine prospective data to determine the change from baseline (week 1 of testing) in resident/bed ratio positive for SARS-CoV-2. |
| Percent of SARS-CoV-2 and bacterial co-infection | 4-8 weeks | Examine prospective data to determine the change from baseline number of healthy \[SARS-CoV-2 naïve\] to number that develop respiratory tract infection. Percent of SARS-CoV-2 positives without a bacterial source of RTI compared to percent of SARS-CoV-2 positives with bacterial co-infection identified by either PCR, symptoms, CXR, CT, throat culture swab, RDT and documented in patient chart. |
| Percent of SARS-CoV-2 and viral co-infection | 4-8 weeks | Examine prospective data to determine the change from baseline number of healthy \[SARS-CoV-2 naïve\] to number that develop respiratory tract infection. Percent of SARS-CoV-2 positives without an additional viral cause identified compared to percent of SARS-CoV-2 positives with viral co-infection identified. |
| Mortality rate due to SARS-CoV-2 infection with bacterial/viral co-infection | 12 months | Examine prospective data to determine the mortality rate (outpatient and inpatient) due to SARS-CoV-2 with additional bacteria and/or virus identified at any time during SARS-Cov-2 PCR positivity prior to death. |
| Mortality rate due to SARS-CoV-2 infection | 12 months | Examine prospective data to determine the mortality rate (outpatient and inpatient) due to SARS-CoV-2 only (no additional bacteria and/or virus identified on PCR at any time during SARS-CoV-2 PCR positivity prior to death. |
| Symptoms of SARS-CoV-2 infection, bacterial co-infection, viral co-infection | Up to 12 weeks post-PCR confirmation for a SARS-CoV-2 positive diagnosis | Any changes in symptom severity will be captured by monitoring the patient's chart for any updates in clinical progress notes. Any symptoms compatible with SARS-CoV-2 infection will be captured such as high temperature, dyspnea, diarrhea, vomiting, myalgia, pharynx pain, abdominal pain, anosmia, cough etc. |
| Percent of SARS-Cov-2 positives and/or bacterial/viral infection with full resolution by 30 days | Up to 30 days after respiratory symptom onset | Examine prospective data to determine the percent of SARS-Cov-2 positives and/or bacterial/viral infection with full resolution by 30 days after respiratory symptom onset \[full resolution defined as resolution of acute onset clinical symptoms\]. |
| Percent of SARS-Cov-2 positives and/or bacterial/viral infection that develop pneumonia-like symptoms | 4-8 weeks | Examine prospective data to determine the percent of SARS-Cov-2 positives and/or bacterial/viral infection that develop pneumonia-like symptoms during SARS-CoV-2 PCR positivity |
| Percent of asymptomatic SARS-Cov-2 positives and/or bacterial/viral infection | 4-8 weeks | Examine prospective data to determine the percent of asymptomatic SARS-Cov-2 positives and/or bacterial/viral infection that never develop symptoms throughout infectious period and are alive/healthy at end of study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Taxon Identification (determined by NGS) | 6-12 months | Defined as intra-community diversity as measured by the total number of detected taxa and distribution of those taxa. |
| BETA Diversity (determined by NGS) | 6-12 months | Defined as inter-community diversity as measured by the total number of detected taxa and distribution of those taxa. |
| Frequency of Detection (Determined by NGS) | 6-12 months | Frequency of detection of the total amount of bacterial DNA/RNA that corresponds to specific bacterial taxa found within nasal swab/ exhaled breath |
| ALPHA Diversity (determined by NGS) | 6-12 months | Defined as intra-community diversity as measured by the total number of detected taxa and distribution of those taxa. |
Countries
United States
Outcome results
None listed